Welcome to This Week in Pharmacy where we touch base on Pharmacy Times Reports on "Community Pharmacy's Existential Question: Should you Chase Product Revenues or Service Margins by Troy Trygstag PharmD. We talk about the Ohio Capital article on PBMs skimming millions of dollars from tax-payers, and Forbes reports on Mark Cuban Cost Plus Drugs is disrupting the PBM contracts and their work with Blue Shield of California. Big time news!! 

Let's talk about Wound Care on This Week in Pharmacy: William Padula, PhD from the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences and-or David G. Armstrong MD from the Keck School of Medicine of USC, are talking with Todd Eury on TWIRx about a recent proposal from Medicare is calling to  eliminate coverage of some of skin substitute therapies, and the potential serious health risks that many Americans will face by limiting them.

Skin substitutes, made from donated amniotic tissue, greatly improve wound care outcomes and help patients avoid limb amputations—a procedure that can double the risk of death for diabetic patients. This Medicare proposal under consideration will deny coverage of over 200 skin substitutes and limit how doctors can properly treat patients will leave tens of thousands of Medicare beneficiaries without treatment.